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Abstract: CX3CL1, which is a chemokine involved in many aspects of human pregnancy, is a
membrane-bound chemokine shed into circulation as a soluble isoform. Placental CX3CL1 is induced
by inflammatory cytokines and is upregulated in severe early-onset preeclampsia. In this study, the
hypothesis was addressed whether angiotensin II can deregulate placental CX3CL1 expression, and
whether CX3CL1 can promote a pro-inflammatory status of monocytes. qPCR analysis of human
placenta samples (n = 45) showed stable expression of CX3CL1 and the angiotensin II receptor AGTR1
throughout the first trimester, but did not show a correlation between both or any influence of
maternal age, BMI, and gestational age. Angiotensin II incubation of placental explants transiently
deregulated CX3CL1 expression, while the angiotensin II receptor antagonist candesartan reversed
this effect. Overexpression of recombinant human CX3CL1 in SGHPL-4 trophoblasts increased
adhesion of THP-1 monocytes and significantly increased IL8, CCL19, and CCL13 in co-cultures
with human primary monocytes. Incubation of primary monocytes with CX3CL1 and subsequent
global transcriptome analysis of CD16+ subsets revealed 81 upregulated genes, including clusterin,
lipocalin-2, and the leptin receptor. Aldosterone synthase, osteopontin, and cortisone reductase were
some of the 66 downregulated genes present. These data suggest that maternal angiotensin II levels
influence placental CX3CL1 expression, which, in turn, can affect monocyte to trophoblast adhesion.
Release of placental CX3CL1 could promote the pro-inflammatory status of the CD16+ subset of
maternal monocytes.
Keywords: first trimester pregnancy; placenta; angiotensin; CX3CL1; inflammation
1. Introduction
The human placenta functions as an interface between the mother and the fetus by fulfilling a
wide-ranging panel of pregnancy maintaining functions, including exchange of gases and metabolites,
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regulation of water balance, dissipation of heat, and secretion of endocrine and immune-modulating
factors. The vast majority of placenta-derived factors are synthesized in the syncytiotrophoblast, which
covers all placental villous trees as well as parts of the inner surfaces of chorionic and basal plates [1].
Besides hormones, cytokines, and growth factors, components of the maternal renin-angiotensin
system (RAS) are considered as potent key players at the maternal-fetal interface. The activity of
maternal RAS is mediated through various ANG peptides and receptors and is suggested to be
influenced at various stages of gestation by contribution from tissue-based RAS in the ovaries and
the uteroplacental unit [2]. The main effector molecule of RAS is angiotensin II (AngII), which acts
on the angiotensin II type 1 receptor (AT1R, encoded by AGTR1) and the AngII type 2 receptor
(AT2R, encoded by AGTR2). Both receptors have been described to be expressed in trophoblast
subpopulations at the maternal-fetal interface, with AT1R predominantly expressed by differentiated
trophoblasts, i.e., the syncytiotrophoblast and extravillous trophoblasts in cell columns, and AT2R
expressed in proliferating villous cytotrophoblasts [3]. Immunohistochemistry located AT1R at the
microvillous plasma membrane of the syncytiotrophoblast, which enables direct interaction with
maternal circulating AngII and, thereby, induction of an endocrine and/or immune-modulating
response by the placenta. Application of AngII stimulates secretion of factors such as placental
lactogen, estradiol, and the soluble form of vascular endothelial growth factor receptor 1 (sFlt-1) from
human placental explants via AT1R [4–6].
Besides acting as powerful vasoconstrictor, AngII is suggested to exert a pro-inflammatory effect
on leukocytes, endothelial cells, and vascular smooth muscle cells [7]. Since maternal plasma AngII
levels are significantly rising from the second trimester of pregnancy onwards [8], it is tempting to
speculate about a role of maternal AngII in inducing an inflammatory response in human placenta.
AngII functions via AT1R as an inflammatory mediator through activation of the nuclear factor-κB
(NF-κB) and activator protein-1 (AP-1) pathways [9–11], which, in turn, induce transcription of
proinflammatory adhesion molecules, cytokines, and chemokines. Chemokines are categorized into
four subfamilies depending on the number and spacing of the first two cysteine residues in a conserved
cysteine structural motif [12]. These four subclasses are referred to as C, CC, CXC, and CX3C, where
C is a cysteine and X is any amino-acid residue. Among the CX3C subclass, CX3CL1 (also referred
to as fractalkine) is synthesized as transmembrane molecule, which can be released as a soluble
isoform into circulation by metalloprotease-dependent shedding [13,14]. CX3CL1 has recently attracted
attention in the field of reproductive research by regulating adhesion and migration processes in
fetal-maternal interaction at different stages of human pregnancy [15]. Furthermore, a growing
body of evidence suggests that a number of pregnancy pathologies, including chorioamnionitis [16],
diabetic pregnancy [17], and severe early-onset preeclampsia (PE) [18,19], are associated with increased
placental CX3CL1 expression. Furthermore, CX3CL1 is elevated in several cardiovascular diseases like
diabetes, obesity, and metabolic syndrome that are also risk factors for an adverse pregnancy outcome
and promotes platelet activation and vascular dysfunction in congestive heart failure [20,21].
Herein, we describe the expression profiles and correlation of human placental CX3CL1 and
AT1R in first trimester gestation, with consideration of the fetal sex, and test the hypothesis whether
exogenously applied AngII, which mimics circulating maternal AngII, can deregulate the expression
of CX3CL1 in human first trimester placenta. Moreover, adhesion of monocyte cell line THP-1
to CX3CL1-overexpressing trophoblasts as well as effects of recombinant human CX3CL1 on the
transcriptome of human primary monocytes were analyzed.
2. Results
In order to determine expression dynamics of placental CX3CL1 and AGTR1 during a human
first trimester pregnancy, placental tissue from non-smoking, lean (BMI < 25), healthy women
(n = 45, Table 1) undergoing elective termination of pregnancy was subjected to quantitative gene
expression analysis.
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Table 1. Baseline characteristics of the study participants.
Characteristics Female (n = 25) Male (n = 20) p Value
Gestational age (days) 56.84 ± 12.62 56.85 ± 13.55 0.998
Fetal crown-rump length (CRL) 1.74 ± 1.27 1.84 ± 1.43 0.797
Placental volume 2.20 ± 1.74 1.86 ± 0.79 0.625
Maternal age (years) 26.68 ± 4.61 25.30 ± 5.45 0.362
Maternal weight (kg) 58.32 ± 7.40 57.25 ± 7.89 0.642
Maternal height (cm) 164.84 ± 4.57 165.25 ± 6.80 0.811
Maternal BMI 21.44 ± 2.34 20.90 ± 1.85 0.399
Data are presented as means ± SD.
Accordingly, both CX3CL1 (Figure 1A) and AGTR1 expression (Figure 1B) revealed no significant
changes among different weeks, which suggests stable expression of both genes throughout the
first trimester gestation. Moreover, no correlation was found for CX3CL1 and AGTR1 (Pearson,
r = −0.009, p = 0.953) and, in a linear regression model, no influence of maternal and fetal factors
could be determined (coefficients were maternal age, BMI, placental volume, fetal crown-rump-length,
gestational age). Notably, the fetal sex did not show a remarkable effect on expression dynamics nor
correlation of both CX3CL1 and AGTR1. However, for placental CX3CL1, the gestational week 7
(p = 0.032) and, for AGTR1, the gestational week 9 (p = 0.036) showed sex-dependent differences in
expression (Mann-Whitney U, two tailed, alpha = 0.05).
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after 6 hours, expression was decreased (0.51-fold) when compared to untreated control (Figure 2B). 
After 24 h, the expression was unchanged (0.95-fold, Figure 2C). Application of the AT1R antagonist 
candesartan reversed the AngII-mediated deregulation of CX3CL1, while candesartan alone did not 
show significant effects. Analysis of CX3CL1 expression in placental explants cultured under the 
same experimental settings for 24 h did not show significant effects of AngII (Figure 2C), which 
suggests a quick and transient response to the AngII stimulus. 
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Figure 1. CX3CL1 and AGTR1 RNA expression in hu an first tri ester placenta. Placental tissue
samples (n = 45) from healthy, lean (B I < 25), non-smoking women with gestational ages ranging
from 5 weeks to 10 weeks were analyzed for CX3CL1 (A) and AGTR1 (B) mRNA expression.
Next, we tested the effect of exogenous AngII on placental CX3CL1 expression in human first
trimester placental explant culture. qPCR analysis of placental explants showed an initial 1.75-fold
upregulation of CX3CL1 expression in response to AngII (0.1 µM) after 3 h (Figure 2A), whereas,
after 6 hours, expression was decreased (0.51-fold) when compared to untreated control (Figure 2B).
After 24 h, the expression was unchanged (0.95-fold, Figure 2C). Application of the AT1R antagonist
candesartan reversed the AngII-mediated deregulation of CX3CL1, while candesartan alone did not
show significant effects. Analysis of CX3CL1 expression in placental explants cultured under the same
experimental settings for 24 h did not show significant effects of AngII (Figure 2C), which suggests a
quick and transient response to the AngII stimulus.
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Figure 2. AngII mediates a transient deregulation of placental CX3CL1. Placental explants were
cultured with or without AngII (0.1 µM) in the presence or the absence of the AT1R antagonist
Candesartan (0.1 µM) for 3 h (A), 6 h (B), and 24 h (C), respectively. Data are presented as median
± IQR (whiskers are min. to max., in A n = 4, in B n = 7, in C n = 7, * p ≤ 0.05) from different
placental tissues.
Having determined the effect of AngII on placental CX3CL1 expression, we next aimed to analyze
the effect of trophoblastic CX3CL1 on the adhesion of monocytes. For this purpose, overexpression
of recombinant human CX3CL1 was established in SGHPL-4 cells. While immunocytochemistry
for CX3CL1 showed only weak staining of control cells (Figure 3A), CX3CL1-overexpressing cells
were distinctly stained (Figure 3B). Immunoblot analysis confirmed immunocytochemistry, which
showed a strong band of approximately 95kDa in CX3CL1 overexpressing cells (Figure 3C). Moreover,
CX3CL1-overexpressing cells substantially released soluble CX3CL1 (Figure 3D), which was generated
in a metalloprotease dependent shedding. Presence of the metalloprotease inhibitor Batimastat,
which has previously been shown to effectively block CX3CL1 shedding in placental explants [22],
almost completely abolished the release of soluble CX3CL1, while, at the same time, the cellular
form accumulated in the cells (Figure 3E). Subsequent adhesion assays revealed a 2.4-fold (p < 0.001)
increased adhesion of the monocyte cell line THP-1 to CX3CL1-overexpressing SGPHPL4 cells, when
compared to control cells (Figure 3F–H).
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Figure 3. CX3CL1 overexpression in trophoblast cell line SGHPL-4 mediates increased
monocyte adherence. SGHPL-4 control cells (A) and CX3CL1 stably overexpressing cells
(SGHPL-4-CX3CL1, B) were stained for CX3CL1 by immunocytochemistry. Western blot (C) confirmed
CX3CL1-overexpression in SGHPL-4-CX3CL1 cells. ELISA showed abundant release of soluble
CX3CL1 in supernatants of SGHPL-4-CX3CL1 after 48 h of culturing (D). Metalloprotease inhibitor
Batimastat, at concentrations of 5 µM and 10 µM, decreased the release of soluble CX3CL1, while cell
associated CX3CL1 accumulated, when compared to the control after 48 h (E). Adhesion assays were
performed with SGHPL-4 control cells (F) and SGHPL-4-CX3CL1 cells (G), which were co-cultured
with fluorescence CellTracker Green pre-labeled THP-1 monocytes for 90 min. Monocyte adhesion was
assessed by acquisition of trophoblast monolayer areas and bound THP-1 cells in phase contrast and
green fluorescence channel, respectively. Pixel areas of bound monocytes were related to pixel areas of
trophoblast monolayers and data for SGHPL-4-control was set as one. Data are from three independent
experiments, using different cell passages and are presented as mean ± SEM *** p ≤ 0.001.
Since increased monocyte to trophoblast adhesion may contribute to a local pro-inflammatory
microenvironment, we next analyzed a panel of 40 cytokines and chemokines released by co-cultures
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of primary monocytes from healthy, female donors in child-bearing age with either CX3CL1
-overexpressing or control SGHPL-4 cells. Among analyzed factors, IL8, CCL19, and CCL13 were
significantly increased and an additional 13 analytes showed a trend to increase, when monocytes
were co-cultured with CX3CL1-SGHPL-4 cells, compared to controls after 6 h (Table 2).
Table 2. Released cytokines and chemokines in co-cultures of SGHPL-4 cells and human
primary monocytes.
Cytokine/Chemokine Aliases Control(pg/mL)
CX3CL1
(pg/mL)
Fold
Change p Value
MIF 5993.0 ± 928.5 5740.5 ± 653.6 0.96 0.6857
IL8 CXCL8 181.7 ± 40.3 347.1 ± 23.1 1.91 0.0286
CCL2 MCP-1 37.5 ± 6.3 47.3 ± 14.6 1.26 0.8857
IL6 26.9 ± 7.7 24.1 ± 1.5 0.89 1.0000
CCL24 eotaxin-2 18.9 ± 12.3 34.9 ± 13.5 1.85 0.3005
IL16 16.4 ± 3.4 23.7 ± 4.1 1.44 0.3429
CCL19 MIP-3β 7.1 ± 2.5 14.5 ± 1.7 2.03 0.0294
CCL13 MCP-4 3.4 ± 0.5 5.8 ± 0.3 1.69 0.0286
CXCL16 SCYB16 3.1 ± 0.6 3.8 ± 0.6 1.25 0.4857
CCL20 MIP-3α 2.8 ± 1.2 9.8 ± 4.6 3.47 0.3429
CCL3 MIP-1α 1.7 ± 0.4 1.8 ± 0.1 1.06 0.8857
CCL8 MCP-2 0.9 ± 0.2 0.4 ± 0.2 0.45 0.3094
CXCL11 I-TAC 0.6 ± 0.4 0.8 ± 0.3 1.26 0.8794
CXCL5 ENA-78 n.d. 198.3 ± 67.5
CXCL1 Gro-α n.d. 62.0 ± 36.6
CCL21 6Ckine n.d. 49.4 ± 9.9
CXCL6 GCP-2 n.d. 13.4 ± 7.8
IL10 n.d. 6.3 ± 0.6
IL1β n.d. 0.5 ± 0.3
Data are presented as mean ± SEM, n = 4, n.d.: not detected, Mann Whitney test.
In order to investigate effects of soluble CX3CL1 on monocytes, we next incubated human
primary monocytes from healthy, female donors with recombinant human CX3CL1. After incubation,
nonclassical (patrolling) and intermediate (pro-inflammatory) CD16+ subsets of monocytes, described
to express the CX3CL1-receptor CX3CR1 [23,24], were isolated and subjected to microarray analysis
of global gene expression profiles. Accordingly, 81 upregulated and 66 downregulated genes were
considered differentially expressed (Figure 4A and Figure S1). Among top upregulated genes were
clusterin (CLU), lipocalin-2 (LCN2), as well as the leptin receptor (LEPR), whereas top downregulated
genes included aldosterone synthase (CYP11B2), osteopontin (SSP1), as well as cortisone reductase
(11beta-hydroxysteroid dehydrogenase Type 1, HSD11B1). In addition, approximately 35% of
deregulated genes were yet uncharacterized loci and analysis of chromosomal location of deregulated
genes revealed two chromosomes (13 and 22) that did not show any deregulated genes (Figure
S2). Ontology-based enrichment analysis of the differentially expressed genes revealed a number
of processes and phenotypes highly connected to the cardiovascular system such as hypertension
or altered response to myocardial infarction (Figure 4B). Lastly, the STRING database derived
protein-protein interaction network analysis suggested deregulation of metabolic pathways, including
steroid hormone biosynthesis, glycerophospholipid metabolism, and mucin type O-glycan biosynthesis
in monocytes incubated with recombinant human CX3CL1 (Figure 4C).
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Thereafter, CD16+ subtypes were subjected to microarray analysis. The heat map of deregulated
genes (A), enrichment heatmap for biological processes from Mammalian Phenotype Ontology and
Jensen DISEASES Ontology with color representing fold change of a g e (B), and protein-protein
interaction networks according to STRING database with an edge thickness re es nting the co fidence
lev l of the interaction with upregeul ted genes i re and downregulated genes in blue (C).
3. Discussion
The present study suggests that maternal AngII levels affect placental CX3CL1 expression
in early human pregnancy. Results from placental explant culture indicate a transient biphasic
AT1R-mediated deregulation of placental CX3CL1 expression, including an initial rapid upregulation
with a subsequent transient downregulation in response to exogenous AngII. This observation is
somehow contrary to previous data obtained in human and murine endothelial as well as vascular
smooth muscle cells [25,26]. Higher AngII concentrations and different cell types used in previous
studies may in part explain this discrepancy. In this case, we used placental explants, where cells
remain in situ, which rather reflects the in vivo situation than cell line monolayers. The lacking
association of placental AGTR1 and CX3CL1 in human first trimester, and their stable expression
levels independent of maternal factors or fetal sex suggests that the response is most likely not a
product of a constitutional increase of receptor expression. Results from previous studies in human
umbilical endothelial cells suggest that AngII-induced CX3CL1 synthesis is secondary to TNF-α
induction [25]. In line with this assumption, TNF-α strongly induces CX3CL1 expression in human first
trimester placenta, and has been suggested as one of the underlying triggers of upregulated CX3CL1
in severe early-onset pre-eclampsia (PE), which is a pathology that is a major contributor to maternal
and neonatal morbidity [18,27]. Besides CX3CL1, an activated RAS, including elevated placental
AT1R expression, higher AngII sensitivity and autoantibodies against the AT1R (AT1-AA) have been
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associated with this multifactorial disease [28–31]. Moreover, oxidative stress, which is generated
by an ischemia-reperfusion type phenomenon, is increasingly recognized as another contributing
factor of PE [32]. In pregnancy, vasoconstriction is mainly regulated by AngII through AT1R signaling,
and ischemia reperfusion type injuries are closely related to the renin-angiotensin-system, which
may possibly increase AngII levels after hypoxia-reoxygenation. This also may induce endothelial
dysfunction, which is one of the key features of PE [33–35]. Furthermore, oxygen fluctuations have been
shown to affect placental RAS and AT1R [36–39], which, in turn, could influence maternal endothelial
dysfunction via AT1-AA and augmented vascular AngII sensitivity [40]. Upon such a change in
maternal AngII levels, membrane-bound CX3CL1 from endomembrane storage compartments could
be rapidly mobilized [41]. This also underlines the possibility of the effects described playing a role in
acute CX3CL1 response to fluctuating AngII levels in PE.
Results from the present study confirm the described CX3CL1-mediated monocyte to trophoblast
adhesion [42] and additionally suggests that binding of monocytes to CX3CL1-expressing trophoblasts
is accompanied by increased secretion of inflammatory cytokines, such as IL-8. This is in line with
our recent finding that a disturbed macrophage-trophoblast crosstalk leads to a pro-inflammatory
milieu and, thereby, contributes to preeclampsia [43]. Besides analysis of secreted cytokines and
chemokines, we performed global transcriptome analysis of primary CD16+ monocytes, which showed
deregulated expression of immune-modulating factors in response to recombinant human CX3CL1.
Among upregulated genes were clusterin, which is an immune modulator described to activate
macrophages [24,25], the acute-phase protein lipocalin-2 [26], and the leptin receptor (LEPR). The
leptin receptor has been suggested to promote oxidative stress and CD16 expression in human
monocytes [27,28]. Among the top downregulated genes were aldosterone synthase (CYP11B2),
which is a key enzyme of aldosterone synthesis [29], osteopontin (SSP1), which has been associated
with monocyte–macrophage differentiation [30], as well as cortisone reductase (HSD11B1), which
generates cortisol from cortisone. Results from transcriptome analysis of CX3CL1-treated primary
monocytes and those of trophoblast-monocyte co-culture are, if at all, hardly comparable and it should
be stressed at this point that CX3CL1 alone might be insufficient to mediate complete adherence
and migration, since a previous study demonstrated that CX3CL1 synergistically acted on monocyte
chemotaxis and adhesion in conjunction with other pro-inflammatory cytokines [44]. Whether or
not, CX3CL1 overexpression induces expression and release of such synergistic factors or other
pro-inflammatory cytokines in trophoblasts remains open and calls for further in depth-analysis.
However, CX3CL1-mediated initiation of monocyte adhesion, by orchestrating a pro-inflammatory
chemotaxis [45], is suggested to induce a shift of the monocyte population towards the CD16+
subset which then predominantly expresses CX3CR1 [46]. Using monocytes from pregnant women
would certainly give more insight into pregnancy-related mechanisms, but, to gain CD16+ monocyte
population in pregnant women, several challenges would have to be met. A paired study design
with isolation before and during pregnancy and the difficulty of obtaining informed consent for
drawing a fairly big amount of blood required for the monocyte isolation when compared to a routine
sampling are some of the biggest difficulties. As an alternative, it would have been interesting to
compare our CD16+ monocytes from non-pregnant women to maternal CD16+ monocytes by using
gene expression databases for single cell populations. However, such a database using the Human Cell
Atlas (https://www.humancellatlas.org/) with entries about maternal monocytes has yet to be created.
Lastly, our results suggest an impact in biological processes like hypertension, abnormal kidney
morphology, myocardial infarction, and myocardium layer morphology. This is in line with the
recently described correlation between inflammatory macrophage expansion and vascular remodeling
in pulmonary hypertension [47] and could be a possible link to the increased risk of early all-cause
mortality of women with a history of preeclampsia that is related to a higher risk for future
cardiovascular events and developing end-stage renal disease [48,49]. STRING database network
analysis suggest that CX3CL1 deregulates key players involved in glycerophospholipid metabolism
and mucin type O-glycan biosynthesis. In the process of monocyte to trophoblast adhesion, mucin type
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o-glycosylation could occur in order to extend the mucin like CX3CL1 stalk, bearing the chemokine
domain and to facilitate monocyte binding [50]. Two residues were identified in the CX3CL1 chemokine
domain, namely Lys-7 and Arg-47 that are important determinants in mediating the interaction of
CX3CL1 with its receptor [51]. The regulation of this metabolic pathway in our microarray analysis
concomitant with the regulation of phospholipid synthesis in CX3CL1 treated peripheral monocytes
may indicate this mucin stalk extension and, on the other hand, reorganization of the GPCR CX3CR1
on the monocyte cell surface via lipid rafts [52].
4. Materials and Methods
4.1. Human Specimen
The study was approved by the ethical committee of the Medical University of Graz (26-132 ex
13/14; 15.1.2014). First trimester placental tissues were obtained between week 5 and 12 of gestation
with written informed consent from women undergoing legal elective surgical pregnancy terminations.
Blood sampling for monocyte isolation was approved by the regional committee of Medical Research
Ethics at the Medical Faculty of Charité Berlin (EA4/145/13; 09.1.2014).
4.2. qPCR Analysis
Placental tissue was homogenized in RNA Lysis Buffer (peqlab, VWR International, Avantor,
Darmstadt, Germany) using an UltraTurrax (IKA) and RNA was isolated, according to the
manufacturer’s instructions (peqlab, VWR International, Avantor, Darmstadt, Germany). RNA
quality was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA). Quality check was followed by reverse transcription of 1µg total RNA per reaction
using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA),
according to the manufacturer’s manual. qPCR was performed with Blue S’Green qPCR Kit (Biozym,
Vienna, Austria) using a Bio-Rad CFX96 cycler and specific primers for CX3CL1 (CX3CL1_For:
CACCTTCTGCCATCTGACTGT and CX3CL1_Rev: GCATGATGCCTGGTTCTGTTG), AGTR1
(AGTR1_For: CTATGGAATACCGCTGGCCC and AGTR1_Rev: TGCAGGTGACTTTGGCTACA),
and CX3CR1 (CX3CR1_For: CGTCATCAGCATTGATAGGTACCT and CX3CR1_Rev:
CTGCACGGTCCGGTTGTT). Fetal sex was determined with specific primers for DDX3Y (DDX3Y_For:
AGTAGAGGCAACCGGCAGTA and DDX3Y_Rev: TGCACTGGAGTAGGACGAGTA) and for
XIST (XIST_For: GACACAAGGCCAACGACCTA and XIST_Rev: TCGCTTGGGTCCTCTATCCA).
Ct values and relative quantification of gene expression were automatically generated by the CFX
Manager 3.1 Software (Bio-Rad Laboratories; Hercules, CA, USA) using the expression of first trimester
placenta specific reference genes YWHAZ and CYC1 [53] as a reference.
4.3. Placental Explant Culture
Placental villous tissue from human first trimester was thoroughly rinsed in PBS (pH 7.0, 37 ◦C,
Gibco, Life Technologies, Thermo Fisher Scientific, Vienna, Austria) and dissected under a stereoscopic
microscope into small pieces of approximately 5 mg moist mass, as described previously [54]. Placental
explants were cultured in six well dishes (Nunc) and 4 mL/well DMEM/F12 (1:1, Gibco) supplemented
with, penicillin/streptomycin, amphotericin B and L-glutamine, without FCS in a hypoxic workstation
(BioSpherix, Redfield, NY, USA) under 2.5% oxygen for indicated time points at 37 ◦C. For treatments,
culture medium was supplemented with Angiotensin II (Sigma-Aldrich, St. Louis, MO, USA) at a
working concentration of 0.1 µM. Candesartan (Selleckchem, Munich, Germany) was used at 0.1 µM
and DMSO at the same volume served as solvent control.
4.4. CX3CL1 Overexpression in SGHPL-4 Cells
Human CX3CL1 coding sequence (sequence ID: NM_002996.4) was amplified by PCR
from cDNA with primers containing restriction sites for cloning into a pCAGGS vector
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(CX3CL1_EcoRI-F: 5′- atc gaattc ATGGCTCCGATATCTCTGTCGT –3′ and CX3CL1_Not1-R: 5′-atc
gcggccgc TCACACGGGCACCAGGACATA –3′). PCR reaction was performed with Phusion
High-Fidelity DNA Polymerase (New England BioLabs; Ipswich, MA, USA) using 50 ng of cDNA
template with 0.2 mM dNTPs, 0.5 µM primers, 3% DMSO in a final volume of 20 µL. Cycling conditions
were: 98.0 ◦C for 30 s, followed by 35 cycles of 98.0 ◦C for 10 s, 66.0 ◦C for 30 s, and 72.0 ◦C for
1.5 min and final extension of 10 min at 72.0 ◦C. The PCR product was extracted from 1% agarose gel,
digested with EcoRI and NotI restriction enzymes, and cloned into the EcoRI/NotI restriction site
of the pCAGGS vector, which results in a CX3CL1 expressing construct under the CAGGS promoter
(pCAGGS-CX3CL1). To generate a construct for stable transgene overexpression, the CAGGS-CX3CL1
cassette was cut out with SspI restriction enzyme from pCAGGS-CX3CL1 and cloned into EcoRV site,
which was generated by site directed mutagenesis into pT2B-puro Sleeping Beauty vector carrying
the SV40-puro cassette for puromycin selection. SGHPL-4 cells were electroporated with a 10:1
ratio of vector carrying CX3CL1 overexpression cassette and plasmid containing Sleeping Beauty
transposase using a Neon Transfection System (Life Technologies, Carlsbad, CA, USA). Two days
post-transfection puromycin selection was carried for two weeks. CX3CL1 overexpressing cells were
referred to as SGHPL-4-CX3CL1 and empty vector harboring cells as SGHPL-4-control cells. SGHPL-4
cells were cultured in Ham’s F-10 medium (Merck) and additionally supplemented with 10 % FCS (v/v),
100 mg/mL streptomycin, and 100 IU/mL penicillin (Gibco, Life Technologies, Carlsbad, CA, USA).
4.5. Culture of Monocyte Cell Line THP-1
The THP-1 cell line was obtained from ECACC and was cultured in RPMI 1640 supplemented
with 10% FCS (v/v), 100 mg/mL streptomycin, and 100 IU/mL penicillin (Gibco, Life Technologies) at
37 ◦C in a humidified atmosphere containing 5% CO2 in air.
4.6. THP-1 Adhesion Assay
THP-1 adhesion experiments were performed as previously described [42]. SGHPL-4-CX3CL1
and SGHPL-4-control cells, respectively, were seeded with a density of 2 × 105 cells/well in 12
well plates. Next day, culture media were replaced by 1 mL RPMI medium containing green
fluorescence (CellTracker GreenCMFDA, Life Technologies, Carlsbad, CA, USA) labeled THP-1 cells
(4 × 105 cells/well), and cells were co-cultured at 37 ◦C for 90 min. After co-culture cells were washed
with PBS three times and were subsequently fixed with 4% formalin (1 mL/well) for 30 min at RT.
THP-1 adhesion was assessed by acquisition of SGHPL-4 monolayer areas (in phase-contrast) and
bound THP-1 cells (green fluorescence channel) in a Cell-IQ system (chipman technologies, Tampere,
Finland). Pixel areas of bound THP-1 cells were related to pixel areas of trophoblast monolayers
in 16 images per well using the Cell-IQ analyzer software (Cell-IQ Analyser v.AN 1.9.0, chipman
technologies, Tampere, Finland).
4.7. Immunocytochemistry
SGHPL-4 cells were seeded in chamber slides (8 × 104 cells/chamber) and cultured for 48 h.
Thereafter, cells were fixed in acetone for 10 minutes and rehydrated in PBS for 5 minutes. Cells
were stained using the UltraVision Large Volume Detection System HRP Polymer Kit (Thermo Fisher
Scientific, Carlsbad, CA, USA), as previously described [55]. In brief, endogenous peroxidase was
blocked with UltraVision hydrogen peroxide block for 10 min. Three washing steps with tris-buffered
saline (TBS + Tween) were followed by Ultra Vision Protein Block including 10% human serum
for 5 min. Polyclonal goat anti-CX3CL1 (2 µg/mL, AF365, R&D Systems) was diluted in Antibody
Diluent (DAKO) and incubated on slides for 45 min at RT. After three TBS washing steps detection was
achieved by incubation with HRP-conjugated rabbit anti-goat antibody (5 µg/mL, P0449, Dako, Agilent
Technologies), and 3-amino-9-ethylcarbacole (AEC, Thermo Scientific), according to the manufacturer’s
instructions. Nuclei were stained with hemalaun and slides were mounted with Kaiser’s glycerol
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gelatine (Merck). Images were acquired with a Leica microscope (Leica DM6000B) and a digital camera
(Olympus DP72, Tokyo, Japan).
4.8. Immunoblotting
After incubation, the cells were washed with PBS and lysed in RIPA buffer (Sigma-Aldrich, Saint
Louis, MO, USA) including protease inhibitor cocktail (Roche Diagnostics; Mannheim, Germany).
Cell lysates were centrifuged at 8000× g and 4 ◦C for 10 min. The concentration of total tissue
protein was determined in clear supernatants according to the Lowry method. Additionally, 30
µg total protein were applied to precast 10% Bis-Tris gels (NuPAGE, Novex, Life Technologies).
Blotting on a 0.45 µm nitrocellulose membrane (Hybond, Amersham Biosciences, GE Healthcare Life
Sciences, Little Chalfont, UK) was followed by analysis of blotting efficiency by Ponceau staining
(Ponceau S solution, Sigma Aldrich). Membranes were cut in horizontal strips at molecular weight
ranges for target proteins. Goat anti-CX3CL1 antibody (2 µg/mL, R&D Systems) and monoclonal
anti-beta actin antibody (12.4 ng/mL, clone AC-15, abcam, Cambridge, UK) were applied to membrane
strips overnight at 4 ◦C. HRP conjugated rabbit anti-goat (1:3000, Dako) and anti-mouse IgG (1:3000,
Bio-Rad), respectively, were used as secondary antibodies and incubated on membranes for 2 h at
RT. Immunodetection was performed with a chemiluminescent immunodetection kit (Western Bright
chemiluminescence Substrate Quantus, Biozym, Austria) according to the manufacturer´s instructions.
Images were acquired with FluorChem Q System (Alpha Innotech, Cell Bioscienes, Santa Clara, CA,
USA).
4.9. Isolation of Human Primary Monocytes
Human primary monocytes were isolated out of 65 ml blood taken from antecubital vein of
female donors (n = 4), by density gradient centrifugation, using Bicoll (Biochrom) to obtain peripheral
blood mononuclear cells (PBMCs), which were subsequently subjected to Pan Monocyte Isolation Kit
(130-096-537, MACS, Miltenyi Biotec), according to the manufacturer’s protocol. The mean purity
of enriched monocytes was 91.5(±0.9)% and was evaluated on a Canto II multicolor flow cytometry
platform (BD). Monocytes were identified after live/dead discrimination and doublet exclusion as
being CD3− CD19− CD14+ using fluorophore-conjugated monoclonal antibodies (Miltenyi Biotec,
Bergisch Gladbach, Germany).
4.10. Co-Culture of SGHPL-4 Cells and Human Primary Monocytes
SGHPL-4-CX3CL1 and SGHPL-4-control cells, respectively, were seeded in 2 mL RPMI medium
with a density of 4 × 106 cells/well in six-well dishes. The next day, media were replaced by 2 mL
RPMI medium containing 6× 105 human primary monocytes per well. After 1 h of incubation at 37 ◦C,
the cells were gently washed with PBS twice and were cultured in 2 mL RPMI medium including
1% FCS for an additional 6 hours at 37 ◦C. After co-culturing, the conditioned culture media were
collected and centrifuged at 1500× g and 4 ◦C for 5 min. The culture media were stored at −80 ◦C for
subsequent multiplex immunoassays.
4.11. Multiplex Immunoassays
Released cytokines and chemokines were analyzed in conditioned culture media using a
panel of 40 magnetic bead-based immunoassays (Bio-Plex Pro Human Chemokine Panel, 40-Plex
#171-AK99MR2; Bio-Rad), and the Luminex200, according to the manufacturer’s manual.
4.12. Stimulation of Human Primary Monocytes with Recombinant Human CX3CL1
Human primary monocytes (5 × 106/mL) were cultured in 5 mL RPMI medium containing
2% FCS in teflon coated bags [56] in the presence or the absence of recombinant human CX3CL1
(50 ng/mL, Biolegend) at 37 ◦C and 10% CO2. After 18 h of culturing, monocytes were collected
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and subjected to isolation of CD16+ monocytes, using the CD16+ Monocyte Isolation Kit (Miltenyi
Biotec), according to the manufacturer’s manual. The primary monocytes were subjected to a two-step
procedure. First, cells were labeled with a non-monocyte depletion cocktail, for labeling and removing
CD15+ granulocytes and CD56+ natural killer cells. Thereafter, the flow through fraction was labeled
with CD16+ magnetic microbeads for positive selection of CD16+ monocytes. CD16 positive selection
was performed to enrich CD16+ monocytes, described to express the CX3CL1-receptor CX3CR1 [23,24].
CX3CR1 expression in CD16+ monocytes was confirmed by qPCR (Figure S3).
4.13. Microarray Analysis
Total mRNA was isolated from CD16+ monocytes using QIAzol lysis reagent and Qiagen RNeasy
mini kit (Qiagen, Hilden, Germany) with on-column deoxyribonuclease I step (Qiagen), according
to the manufacturer’s protocol. mRNA quality and concentration was measured by Agilent RNA
Kits for the 2100 bioanalyzer. Isolated RNA was converted to DNA and biotin labeled in preparation
for transcriptome analysis using the GeneChip® WT PLUS Reagent Kit (Affymetrix, Thermo Fisher
Scientific). cDNA was hybridized to Affymetrix HuGene 2.0 ST Array Format 49 Chips, according
to the manufacturer’s instructions. Chips were then scanned in the GeneChip® Scanner 3000 7G
using Affymetrix GeneChip Command Console software. Microarray data have been deposited in
the ArrayExpress database [57] at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number
E-MTAB-7484, according to community guidelines, including the “Minimal Information about a
Microarray Experiment” (MIAME) [58].
Background subtraction, quantile normalization, and summarization of raw microarray probe
intensity values were done with RMA function from the oligo R package. Custom CDF from Brainarray
project [59], version 22.0.0, was used to summarize and annotate the probes to Entrez Gene ID.
Quality control was done with ArrayQualityMetrics [60] and factoextra (http://www.sthda.com/
english/rpkgs/factoextra) R packages. Differential expression analysis was performed with the
limma R package [61]. Due to a low sample size, p-values < 0.01 were considered as alternative to
false discovery rate correction (FDR), according to MAQC/SEQC recommendations [62]. EnrichR
R package was used for functional enrichment analysis as well as EnrichR [63] and ShinyGO web
services (http://bioinformatics.sdstate.edu/go/). FDR adjusted p-value < 0.05 and the top highest
EnrichR combined score were used when selecting enriched functional categories. The protein-protein
interaction network was extracted from STRING dababase version 11 [64]. Namely, after supplying
differentially expressed genes list, we filtered out disconnected nodes and low confidence interactions
(< 0.4), which resulted in the network in Figure 4C. Plots were produced with pheatmap (https://cran.
r-project.org/web/packages/pheatmap/index.html), karyotypeR [65], EnhancedVolcano (https://doi.
org/doi:10.18129/B9.bioc.EnhancedVolcano), and ggplot2 (https://cran.r-project.org/web/packages/
ggplot2/index.html) R packages. Genes’ chromosomal locations were obtained with the biomaRt R
package [66]. All the computations were done using Bioconductor version 3.6 (BiocInstaller 1.28.0,
City, Country) [67] and R version 3.4.4. The source code together with quality control plots is available
from a dedicated github repository (https://github.com/sysbio-vo/article-fractalkine-suppl).
4.14. Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics 23 and R 3.5.0. Graphs were created
with GraphPad Prism. Obtained data was first analyzed for normal distribution with the Shapiro-Wilk
test and the statistically appropriate tests were then chosen, according to the results. Alpha was set at
0.05 and adjusted for multiple testing and alpha-error-accumulation with a Bonferroni correction when
needed. For non-parametric analysis of dependent variables, the Friedman’s test was applied as well
as the Dunn’s post hoc test, whereas the Pearson correlation coefficient were calculated for normally
distributed data. Homogeneity of variances was tested for by Levene’s test and, when appropriate,
Welch’s correction was used. A linear regression model was applied in the cohort data for the analysis
of possible influencing factors.
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5. Conclusions
In summary, our data suggest that fluctuations in maternal AngII levels are followed by an
immediate upregulation of placental CX3CL1, which, in turn, can contribute to a pro-inflammatory
micro-environment by activating patrolling and intermediate monocyte subsets. While the major
strength of this study is the use of a high case number of well-characterized human first trimester
placental tissues, the use of primary monocytes obtained from non-pregnant women may represent
a limitation. Pregnant women were shown to have an increased percentage of nonclassical and
intermediate monocytes compared to nonpregnant women, and preeclamptic women had an even
higher fraction of CD16+ monocytes than pregnant women, which was caused by a selective
increase [68]. CX3CL1 promotes CD16 expression of monocytes and their survival [69]. Therefore,
our findings support a role of placental CX3CL1 in the pathological increase of intermediate and
nonclassical monocytes in preeclamptic women through an AngII mediated mechanism, which is
partly responsible for a pro-inflammatory setting.
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